Skip to Main Content

Paper Details

Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Am J Hematol
1
2023
Author NameAffiliation
Farhad RavandiUniversity of Texas M. D. Anderson Cancer Center
Gautam BorthakurUniversity of Texas M. D. Anderson Cancer Center
Courtney D DiNardoUniversity of Texas M. D. Anderson Cancer Center
Rashmi Kanagal-ShamannaUniversity of Texas M. D. Anderson Cancer Center
Guillermo Garcia-ManeroUniversity of Texas M. D. Anderson Cancer Center
Hagop KantarjianUniversity of Texas M. D. Anderson Cancer Center
  • 1 - 6

Datasets

Release 1.2